BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25512459)

  • 1. No pain, no gain: a fallacy so far.
    Gradishar WJ
    J Clin Oncol; 2015 Jan; 33(3):235-7. PubMed ID: 25512459
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
    Stearns V; Chapman JA; Ma CX; Ellis MJ; Ingle JN; Pritchard KI; Budd GT; Rabaglio M; Sledge GW; Le Maitre A; Kundapur J; Liedke PE; Shepherd LE; Goss PE
    J Clin Oncol; 2015 Jan; 33(3):265-71. PubMed ID: 25512454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letrozole or tamoxifen in early breast cancer.
    Buzdar AU; Baum M; Cuzick J
    N Engl J Med; 2006 Apr; 354(14):1528-30; author reply 1528-30. PubMed ID: 16598051
    [No Abstract]   [Full Text] [Related]  

  • 4. Lichen sclerosus in breast cancer survivor.
    Vieira-Baptista P
    J Gen Intern Med; 2013 Mar; 28(3):344. PubMed ID: 23299266
    [No Abstract]   [Full Text] [Related]  

  • 5. Lichen sclerosus in a breast cancer survivor.
    Moore KA; Potter JE
    J Gen Intern Med; 2013 Mar; 28(3):345. PubMed ID: 23288380
    [No Abstract]   [Full Text] [Related]  

  • 6. ATAC trial update.
    Del Mastro L; Venturini M
    Lancet; 2005 Apr 2-8; 365(9466):1225; author reply 1225-6. PubMed ID: 15811447
    [No Abstract]   [Full Text] [Related]  

  • 7. Aromatase inhibitor-associated arthralgias: Pathogenesis, frequency and management.
    Altundag K; Dede D; Harputluoglu H; Gullu I
    Joint Bone Spine; 2007 Dec; 74(6):662-3. PubMed ID: 17913550
    [No Abstract]   [Full Text] [Related]  

  • 8. Anastrozole-induced hepatotoxicity.
    Zapata E; Zubiaurre L; Bujanda L; Piérola A
    Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1233-4. PubMed ID: 17033446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aromatase inhibitors and arthralgia].
    Nagykálnai T; Landherr L; Mészáros E
    Magy Onkol; 2011 Mar; 55(1):32-9. PubMed ID: 21617789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended adjuvant therapy for breast cancer--how much is enough?
    Prowell TM; Stearns V
    J Natl Cancer Inst; 2007 Dec; 99(24):1825-7. PubMed ID: 18073372
    [No Abstract]   [Full Text] [Related]  

  • 11. Severe disabling tendinopathy caused by anastrazole.
    Martens HA; Schröder CP; van der Eerden PJ; Willemse PH; Posthumus MD
    Rheumatology (Oxford); 2007 Oct; 46(10):1619-21. PubMed ID: 17726034
    [No Abstract]   [Full Text] [Related]  

  • 12. [Intensification of a diffuse chronic pain syndrome by the introduction of an aromatase inhibitor].
    Nemitz N; Kurmann PT; Van Linthoudt D
    Praxis (Bern 1994); 2008 Feb; 97(3):137-41. PubMed ID: 18549014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.
    Ingle JN
    Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S17. PubMed ID: 21172079
    [No Abstract]   [Full Text] [Related]  

  • 14. Rheumatoid arthritis and aromatase inhibitors.
    Bertolini E; Letho-Gyselinck H; Prati C; Wendling D
    Joint Bone Spine; 2011 Jan; 78(1):62-4. PubMed ID: 20621535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.
    Lycette JL; Luoh SW; Beer TM; Deloughery TG
    Breast Cancer Res Treat; 2006 Oct; 99(3):249-55. PubMed ID: 16752073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.
    Sestak I; Sapunar F; Cuzick J
    J Clin Oncol; 2009 Oct; 27(30):4961-5. PubMed ID: 19752338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATAC trial update.
    de Castro G
    Lancet; 2005 Apr 2-8; 365(9466):1225; author reply 1225-6. PubMed ID: 15811448
    [No Abstract]   [Full Text] [Related]  

  • 18. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
    Ingle JN; Schaid DJ; Goss PE; Liu M; Mushiroda T; Chapman JA; Kubo M; Jenkins GD; Batzler A; Shepherd L; Pater J; Wang L; Ellis MJ; Stearns V; Rohrer DC; Goetz MP; Pritchard KI; Flockhart DA; Nakamura Y; Weinshilboum RM
    J Clin Oncol; 2010 Nov; 28(31):4674-82. PubMed ID: 20876420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
    Bruntsch U
    MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697
    [No Abstract]   [Full Text] [Related]  

  • 20. Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
    Winters L; Habin K; Gallagher J
    Clin J Oncol Nurs; 2007 Jun; 11(3):433-9. PubMed ID: 17623627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.